PT-141
PT-141 is bremelanotide. Vyleesi is its approved product for a specific HSDD population; that label does not establish a sexual-performance regimen for men.
Technical catalog description
PT-141 is a synthetic melanocortin receptor agonist derived from the tanning peptide Melanotan II. Unlike PDE5 inhibitors (Viagra, Cialis), it works centrally through the hypothalamus rather than through peripheral vascular effects, making it the only peptide that directly addresses the neurological component of sexual function.
It is used by both men and women to restore libido, improve sexual response, and treat hypoactive sexual desire disorder (HSDD). Its central mechanism means it can help cases where PDE5 inhibitors fail, including psychogenic erectile dysfunction and low-desire states driven by hormonal suppression from AAS use.
Read next
PT-141’s appeal in performance circles is specific. AAS use reliably suppresses natural testosterone and can dramatically reduce libido and sexual function even when performance remains good. PT-141 addresses this from a completely different angle than testosterone restoration. It acts centrally on the brain’s sexual response circuitry rather than through peripheral hormone levels.
This makes it uniquely useful during and after cycles where libido loss is a quality-of-life issue but where full hormonal normalization takes time. It is also used simply because it works, often better than PDE5 inhibitors for desire rather than just mechanical function.
Nausea, the most common and often dose-limiting side effect
Flushing, transient blood pressure increase, and spontaneous erections in men
blood pressure if symptomatic
Uncontrolled hypertension or cardiovascular risk without clearance
Users who cannot tolerate nausea and refuse to start at a low dose
PT-141 is chosen for two situations. The first is AAS-related libido suppression where testosterone levels may still be present but the central drive is blunted. The second is a straightforward desire for reliable libido and sexual performance enhancement on demand. Women also use it for HSDD, which makes this compound unusual in being meaningfully used across genders.
It works acutely, typically within 45–90 minutes of injection. The effect duration is 6–12 hours for most users. Nausea peaks within the first 1–2 hours and usually subsides on its own.
Source reference information
Product reference · specific HSDD population. PT-141 name alone does not identify the approved product, population or clinical indication. References remain separate from quantities entered in a plan.
Label regimen: 1.75 mg/as needed. As needed; at least 45 minutes before anticipated sexual activity. Vyleesi product reference. Population: Premenopausal women with acquired generalized HSDD meeting the label conditions. Route: subcutaneous; formulation: Vyleesi bremelanotide injection. Not indicated in men, postmenopausal women or to enhance sexual performance. No more than one dose in 24 hours; more than eight doses/month is not recommended. Contraindicated with uncontrolled hypertension or known cardiovascular disease; label contains other warnings. Source: Vyleesi prescribing information.
A generic PT-141 profile does not establish daily, as-needed, or repeat-administration instructions. Product formulation and indication must be identified before using product instructions.
Compared with Melanotan II, PT-141 is the active fragment responsible for the sexual effects without the prolonged tanning. Compared with PDE5 inhibitors, it addresses desire and central drive rather than just the vascular mechanics of erection.